Clinical trial
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal…
NCT00038467 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00038467 |
|---|---|
| Title | Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer |
| Official title | Randomized Double-Blind Trial In Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen For 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen |
| Acronym | IES |
| Lead sponsor | Pfizer, Industry |
| Collaborators | International Collaborative Cancer Group |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Tamoxifen, Exemestane |
| Enrollment | 4,740 |
| Start date | Feb 1, 1998 |
| Primary completion | Jun 1, 2003 |
| Completion | Mar 1, 2013 |
| First posted | Jun 3, 2002 |
| Last update posted | May 7, 2014 |
| Countries | Argentina, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany and 25 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: